Histopathological grading affects survival in patients with isocitrate dehydrogenase-wildtype gliomas.

ABSTRACT:

Background

The World Health Organization (WHO) Classification of Tumors of the Central Nervous System (2021) defines lower-grade (WHO grade II/III) isocitrate dehydrogenase (IDH) wild-type astrocytoma as glioblastoma, IDH-wildtype, WHO grade 4. However, this definition is conditional. Notably, the traditional histopathological grade is no longer used, and the independent prognostic factor of tumor grade in IDH wild-type gliomas remains unclear. In this study, we aimed to determine if histopathological grade is an independent prognostic factor.

Methods

The clinical data and pathological information of 647 patients with IDH wild-type gliomas from the Chinese Glioma Genome Atlas (CGGA) database (2006-2019) were retrospectively analyzed. All patients were stratified according to

SUBMITTER: Hou Z 

PROVIDER: S-EPMC12479321 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature